Acne’s Unseen Pain

This expert panel fields multidisciplinary questions on maskne, compliance, access to care and more.

Acne patients are benefitting from a robust pipeline with treatments that hold promise for increased efficacy and safety. First-in-class additions to the FDA-approved armamentarium, such as the novel antiandrogen clascoterone (Winlevi; Sun Pharma), give dermatologists and pediatricians new tools to combat this skin condition. Speakers offer insights on matching medications to individual patient needs and controlling costs.

Panelists provide pearls on how to make a smarter diagnosis, tailor treatment plans to patients’ lifestyles and preferences, and motivate pediatric patients to adhere to their treatment plan.

Should physicians ask parents to leave the exam room to ensure a pediatric patient’s privacy and comfort level? Or is acne a family matter? Will pediatric patients talk openly about the physical and psychological burdens of this skin condition or does the physician need input from parents? Find out the cues, clues, and conversational tips to get to the roots of acne’s impact.

The initial visit with a pediatric or adolescent patient with acne and their parent or guardian goes beyond obtaining a detailed medical history. The conversation needs to address a broad range of acne’s physical symptoms and psychological effects on the patient and their family. The panelists offered best practices on how to drill down for that information within the limitations of time and scope each individual doctor faces.

Acne may be the most common skin condition in the United States, with various studies estimating 79% to 95% of Americans age 12 to 24 experience at least a minor case, but diagnosing, treating, and managing care for pediatric patients affected by it has never been more complex. Dermatology Times® and its sister brands, Contemporary Pediatrics® and Psychiatric Times™, asked thought leaders across disciplines to share their insights as speakers for this exclusive webinar.